Flatulence
Octagon Therapeutics Ceases Operations Due to R&D Challenges and Unresolved Biology Questions
Autoimmune disease biotech, B cell immunomodulator program, OCT50 program, Novo Nordisk alliance, Winding down operations, Unresolved biology challenges
MEI Pharma’s Leadership Shakeup: CEO and Medical Head Step Down Amidst Wind-Down Considerations
MEI Pharma, wind down, CEO, medical head, strategic alternatives